While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
Not all companies are created equal, and StockStory is here to surface the ones with real upside. Keeping that in mind, here are three cash-producing companies that don’t make the cut and some better opportunities instead.
fuboTV (FUBO)
Trailing 12-Month Free Cash Flow Margin: 8.2%
Originally launched as a soccer streaming platform, fuboTV (NYSE:FUBO) is a video streaming service specializing in live sports, news, and entertainment content.
Why Is FUBO Risky?
- Sluggish trends in its domestic subscribers suggest customers aren’t adopting its solutions as quickly as the company hoped
- Historical operating margin losses point to an inefficient cost structure
- Low free cash flow margin of 0.7% for the last two years gives it little breathing room, constraining its ability to self-fund growth or return capital to shareholders
fuboTV’s stock price of $2.66 implies a valuation ratio of 88.3x forward P/E. To fully understand why you should be careful with FUBO, check out our full research report (it’s free for active Edge members).
Gibraltar (ROCK)
Trailing 12-Month Free Cash Flow Margin: 9.3%
Gibraltar (NASDAQ:ROCK) makes renewable energy, agriculture technology and infrastructure products. Its mission statement is to make everyday living more sustainable.
Why Does ROCK Fall Short?
- Customers postponed purchases of its products and services this cycle as its revenue declined by 7.4% annually over the last two years
- Projected sales growth of 4% for the next 12 months suggests sluggish demand
- Earnings growth over the last two years fell short of the peer group average as its EPS only increased by 3.1% annually
At $49.19 per share, Gibraltar trades at 10.9x forward P/E. If you’re considering ROCK for your portfolio, see our FREE research report to learn more.
Collegium Pharmaceutical (COLL)
Trailing 12-Month Free Cash Flow Margin: 38.2%
Pioneering abuse-deterrent technology in a field plagued by addiction concerns, Collegium Pharmaceutical (NASDAQ:COLL) develops and markets specialty medications for treating moderate to severe pain, including abuse-deterrent opioid formulations.
Why Is COLL Not Exciting?
- Modest revenue base of $757.1 million gives it less fixed cost leverage and fewer distribution channels than larger companies
- Waning returns on capital imply its previous profit engines are losing steam
Collegium Pharmaceutical is trading at $48.86 per share, or 6.4x forward P/E. Read our free research report to see why you should think twice about including COLL in your portfolio.
High-Quality Stocks for All Market Conditions
If your portfolio success hinges on just 4 stocks, your wealth is built on fragile ground. You have a small window to secure high-quality assets before the market widens and these prices disappear.
Don’t wait for the next volatility shock. Check out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today.